Showing 3081-3090 of 5805 results for "".
- Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiationshttps://practicaldermatology.com/news/20140530-valeant_and_pershing_square_make_revised_offer_for_allergan_contingent_on_good_faith_negotiations/2459224/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it is making an offer for Allergan, Inc. (NYSE: AGN) under which each Allergan share would be exchanged for $72.00 in cash and 0.83 shares of Valeant common stock, based on the fully diluted number of
- FDA to Require Warnings on Sunlamp Productshttps://practicaldermatology.com/news/20140530-fda_to_require_warnings_on_sunlamp_products/2459227/The FDA issued a final order reclassifying sunlamp products and ultraviolet (UV) lamps intended for use in sunlamp products from low-risk (class I) to moderate-risk (class II) devices. The order also requires that sunlamp products carry a visible black-box warning on the device
- Allergan Physician Customers Voice Strong Support Following Allergan's Rejection of Unsolicited Proposal to Acquire Companyhttps://practicaldermatology.com/news/20140521-allergan_physician_customers_voice_strong_support_following_allergans_rejection_of_unsolicited_proposal_to_acquire_company/2459232/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today announced that it has received a strong outpouring of support from its physician customers, their nurses and office staff members, as well as from patient advocacy groups and medical associations, following the Company's rejection of Val
- Clinical Trial Finds New Cream Diminishes Symptoms of Psoriasis, Eczemahttps://practicaldermatology.com/news/20140516-clinical_trial_finds_new_cream_diminishes_symptoms_of_psoriasis_eczema/2459237/Findings from an independent study indicate that the antioxidant-based Psorzema Crème formula from derma e® diminishes symptoms of eczema and psoriasis. In an eight-week study, symptomatic participants used Psorzema® Crème, all of whom showed significant improvement in dryness and flak
- Potential New Diagnostic Tools and Therapies for Melanoma in the Foreseeable Futurehttps://practicaldermatology.com/news/20140512-potential_new_diagnostic_tools_and_therapies_for_melanoma_in_the_foreseeable_future/2459241/Oregon State University researchers have identified a biochemical process that may cause normal and healthy skin cells to transform into cancerous melanoma cells. These findings could help predict melanoma exposure and could also lead to future treatments. Melanoma, the deadliest form of
- Survey Finds Rosacea Sufferers' More Likely to be Judged Negatively Upon First Impressionhttps://practicaldermatology.com/news/20140428-survey_finds__rosacea_sufferers_more_likely_to_be_judged_negatively_upon_first_impression/2459251/A new survey by the National Rosacea Society finds that rosacea sufferers' are often judged negatively upon first impression. Shy, nervous, and stressed are the three words respondents used to describe their view of an individual with redness on their face, without knowing anything about them.
- XOMA Finalizes Gevokizmab Phase III Clinical Program in Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140428-xoma_finalizes_gevokizmab_phase_3_clinical_program_in_pyoderma__gangrenosum/2459254/Xoma Corporation finalized the plans for gevokizumab Phase III Program in Pyoderma Gangrenosum (PG). The Phase III Study will include two double-blind placebo-controlled clinical studies with 60 patients who have active PG. Paul Rubin, Senior Vice President,
- ALPHAEON Launches New Patient Financing Solutionhttps://practicaldermatology.com/news/20140425-alphaeon_launches_new_patient_financing_solution/2459256/ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings, LLC, launched ALPHAEON CREDIT, which the company describes as a new tool for patients seeking to finance self-pay lifestyle healthcare procedures through board-certified specialty physicians in dermatology, ophthalmology, plast
- Foamix Gains Five Additional US Patentshttps://practicaldermatology.com/news/20140421-foamix_gains_five_additional_us_patents/2459263/The United States Patent and Trademark Office (USPTO) issued Foamix five new patents covering its technologies. Foamix, a specialty pharmaceutical company, focuses on developing and commercializing proprietary topical foams. The additional five patents raises Foamix's number to 25 United
- Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lineshttps://practicaldermatology.com/news/20140421-revance_therapeutics_announces_positive_results_from_the_rt002_phase_12_study_in_glabellar_frown_lines/2459262/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. RT002 is Revance's proprietary, injectable botulinum toxin investigational product that incorpo